Zacks Investment Research upgraded shares of Corbus Pharmaceuticals, Inc. (CRBP) from N/A to OUTPERFORM on January 07, 2015, with a target price of $6.00.
We are initiating coverage of Corbus Pharmaceuticals, Inc. (OTC: CRBP) with an Outperform' rating and a $6.00 price target. Corbus is developing treatments for life-threatening rare chronic inflammatory conditions. The company's lead compound is Resunab , a first-in-class oral anti-inflammatory / anti-fibrotic drug that is set to begin Phase 2a clinical trials for the treatment of cystic fibrosis and diffuse systemic sclerosis (scleroderma). Resunab has been tested in over 100 subjects in Phase 1 clinical trials with no safety concerns reported. The compounds unique mechanism of action has the potential to distinguish Resunab from other anti-inflammatory medications currently available.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Corbus Pharmaceuticals, Inc. (CRBP),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment